AL-ADTRAN
13.3.2023 14:01:39 CET | Business Wire | Press release
Adtran®, Inc., (NASDAQ:ADTN), the leading provider of next-generation open and disaggregated networking solutions, and Satelles, Inc., the leading supplier of secure time and location technology using low-earth orbit (LEO) satellites, today announced a strategic partnership. The collaboration will enable operators of critical infrastructure to safeguard their timing networks with Satellite Time and Location (STL) technology. By integrating Satelles’ STL into its Oscilloquartz network synchronization products, Adtran will provide an alternative to GNSS systems or a way to augment them with enhanced reliability and security. With the ability to deliver highly precise PNT service, even in GNSS-denied applications, STL offers a vital resource for mobile operators, power utility companies, government, scientific research and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005475/en/
Adtran’s partnership with Satelles will further strengthen its aPNT+™ solution. (Photo: Business Wire)
“We’re pleased to be working with Adtran’s Oscilloquartz division to integrate STL into its portfolio of PTP network timing devices. Together, we’re enabling even more customers to benefit from their game-changing aPNT+™ technology,” said Christina Riley, VP and GM of commercial enterprise solutions at Satelles. “Leveraging LEO signals that are 1,000 times stronger than GNSS, our STL solution is transforming the PNT industry. It’s ideal for providing accurate, reliable timing where GNSS can’t reach, such as indoor locations. And in settings where it is possible to receive GNSS signals, STL complements it with additional PNT services to improve resiliency. Easy and affordable to install, STL also offers new levels of security for synchronization network infrastructure.“
STL provides augmented and secure backup for GPS or other GNSS by harnessing encrypted signals transmitted via LEO satellites. It ensures timing and location information that is highly precise, robustly secure, and accessible worldwide. STL is effectively impervious to cyberattacks and is far less susceptible to GNSS vulnerabilities such as signal disruption and manipulation. And because STL signals are up to 1,000 times stronger than GNSS, they can easily reach into buildings and other hard-to-reach locations. Through its partnership with Satelles, Adtran’s Oscilloquartz division will incorporate these benefits into its end-to-end timing toolkit. What’s more, as well as integrating STL into its grandmaster clocks, it will develop miniature M.2 form factor STL receiver modules for third-party product integration.
“We’re excited to offer Satelles’ innovative STL technology as the perfect addition to our portfolio. Reliable, precise and secure, STL is an excellent source of alternative PNT services that’s ideal for use in situations where distributed PTP is unavailable. It also creates new market opportunities for indoor 5G and data center use cases. By incorporating it into our solutions, we’ll empower operators of mission-critical networks to bring robust timing to the most challenging environments and remove the expense of installing outdoor antennas and coring through concrete,” commented Gil Biran, GM of Oscilloquartz, Adtran. “This partnership reinforces our commitment to providing the most advanced and reliable network timing solutions available, and we look forward to bringing the advantages of STL to customers around the world.”
About Adtran
Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. Adtran, Inc. is a wholly-owned subsidiary of ADTRAN Holdings, Inc. (NASDAQ:ADTN and FSE: QH9). Find more at Adtran, LinkedIn and Twitter.
About Satelles
Satelles protects critical infrastructure by providing STL as an alternative positioning, navigation, and timing (PNT) technology that delivers stability, reliability, and trust required by commercial enterprises and government entities. STL’s secure signal from low Earth orbit (LEO) is resilient to regional outages of GPS and other GNSS. Customers turn to Satelles for a primary source of PNT, and STL also safeguards against devastating attacks to GPS/GNSS capable of disrupting or disabling electrical grids, wireless communications networks, financial systems, and other private and public infrastructure. Built on a foundation of expertise in the public sector, Satelles delivers first-to-market proven technology that is sold commercially throughout the world today. Learn more at www.satelles.com.
Published by
Adtran, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005475/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
